skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.04d (Release date: 2017-04-24)
SearchBox Top
SearchBox Bottom
ALK Inhibitor X-396 (Code C102754)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: ALK Inhibitor X-396

Definition: An orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic activity. Upon oral administration, X-396 binds to and inhibits ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors; ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.

Display Name: ALK Inhibitor X-396

Label: ALK Inhibitor X-396

NCI Thesaurus Code: C102754 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL437011  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
ALK Inhibitor X-396
Anaplastic Lymphoma Kinase Inhibitor X-396

External Source Codes: 
PDQ Closed Trial Search ID 735953
PDQ Open Trial Search ID 735953 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C102754
Contributing_Source CTRP
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom